Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed

 
• By Derrick Gingery
Workload
Meetings and manufacturing supplements are estimated to rise in FY 2022, while one less biosimilar application is expected, compared to the current fiscal year. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics